Clinical Trial Update: Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating silymarin as an adjunct therapy on proteinuria in type 2 diabetes patients on renin-angiotensin system inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: Lahore General Hospital | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED